Abstract Number: 2514 • ACR Convergence 2023
Myositis Triad Subset Is Associated with High Mortality in Immune Checkpoint Inhibitor- Induced Myositis
Background/Purpose: Myositis is an infrequent but serious complication associated with immune check point inhibitor (ICI) treatment. Many patients with ICI-induced myositis will develop concurrent myocarditis…Abstract Number: 0361 • ACR Convergence 2023
Safety of Golimumab Dose Escalation in Pediatric Autoimmunity: A Single Institution Retrospective Experience
Background/Purpose: There is limited data on pediatric golimumab dose escalation, with some data available only in the adult literature. The subcutaneous formulation is not approved…Abstract Number: 0458 • ACR Convergence 2023
Drug Switching Due to Inefficacy in Rheumatoid Arthritis Patients Treated with Biological and Targeted Therapies. Daily Clinical Experience
Background/Purpose: The treatment of Rheumatoid Arthritis (RA) has undergone an enormous change in the last two decades with the use of biological Disease Modifying Drugs…Abstract Number: 0592 • ACR Convergence 2023
Real-World Treatment Patterns in Patients with Systemic Lupus Erythematosus: An Analysis of the SLE Prospective Observational Cohort Study (SPOCS)
Background/Purpose: The international SLE Prospective Observational Cohort Study (SPOCS) collected data on patients with moderate to severe SLE disease activity from June 2017 through November…Abstract Number: 0971 • ACR Convergence 2023
Network Meta Analyses of the Effectiveness and Safety Profiles of Janus Kinase Inhibitors and Biologic Agents in Treating Children with Non-systemic Juvenile Idiopathic Arthritis (nsJIA)
Background/Purpose: Tofacitinib (TOFA, NCT02592434) and Baricitinib (BARI, NCT03773978) are Janus kinase inhibitors (JAKi) that are approved for or being tested for nsJIA treatment. We aim…Abstract Number: 1167 • ACR Convergence 2023
Transcriptome Analysis of Peripheral Blood Reveals Superiority of the Triple Combination of Baricitinib, Rituximab, and Tacrolimus Therapy (BRT-Tx.) for anti-MDA5 Antibody-positive Dermatomyositis (MDA5-DM)
Background/Purpose: MDA5-DM is characterized by high mortality due to rapid progressive ILD. We reported that in MDA-5DM, (1) RIG-1-like receptor signaling is enhanced, (2) antiviral…Abstract Number: 1379 • ACR Convergence 2023
Population Pharmacokinetic/Pharmacodynamic Modeling of Dazodalibep, a CD40L Antagonist, in Healthy Volunteers and Patients with Rheumatoid Arthritis and Sjogren’s Syndrome
Background/Purpose: Sjögren's (SjS) is a chronic, systemic autoimmune disease caused by aberrant activation and infiltration of lymphocytes. Dazodalibep (DAZ), a novel non-antibody biologic antagonist of…Abstract Number: 1504 • ACR Convergence 2023
Characteristics and Prior Treatment Journey of Systemic Lupus Erythematosus (SLE) Patients Who Were Prescribed Anifrolumab — Observations from the American Rheumatology Network (ARN) in the U.S
Background/Purpose: FDA-approved for moderate-severe SLE in August 2021, anifrolumab is a type I interferon (IFN) receptor antagonist that has been shown to decrease lupus flares…Abstract Number: 1962 • ACR Convergence 2023
Toll-Like Receptor 7/8 Activation of Immune and Non-Immune Cells in Muscle by RNA-Containing Immune Complexes Can Contribute to Inflammation and the Pathogenesis of Myositis
Background/Purpose: Tissue inflammation is a major disease driver in idiopathic inflammatory myopathies (IIM), leading to muscle weakness and, in the case of dermatomyositis (DM), a…Abstract Number: 2193 • ACR Convergence 2023
Anti-citrullinated Protein Antibodies in Sjögren’s Syndrome Define a Subset of Patients with Lower B Cell Activation Markers and Higher Risk of Lung Involvement
Background/Purpose: Extraglandular manifestations may occur in up to 40-50% of patients with SS, including inflammatory arthralgia and chronic polyarthritis (1-3). ACPA are prototypical markers of…Abstract Number: 2251 • ACR Convergence 2023
Direct and Indirect Effects of Upadacitinib or Adalimumab on Pain in Psoriatic Arthritis: Results from a Randomized Phase 3 Study
Background/Purpose: Pain, including inflammatory joint pain, may be debilitating in patients with psoriatic arthritis (PsA). Pain in PsA is multidimensional and can be influenced via…Abstract Number: 2537 • ACR Convergence 2023
Implementation of a Best Practice Advisory to Improve Infection Screening Prior to New Prescriptions of Biologics and Targeted Synthetic Drugs
Background/Purpose: Biologic and targeted synthetic DMARDs (b/tsDMARDs) are widely used to treat patients with various autoimmune inflammatory diseases (ARD). Use of a b/tsDMARD in patients…Abstract Number: 0376 • ACR Convergence 2023
Switching Patterns of Biological and Targeted Synthetic Therapies in Juvenile Idiopathic Arthritis
Background/Purpose: New therapies have improved the therapeutic management of juvenile idiopathic arthritis (JIA), allowing disease control in cases that are refractory or intolerant to methotrexate.…Abstract Number: 0477 • ACR Convergence 2023
Continuing TNFi After Pregnancy Diagnosis in Women with Chronic Rheumatic Inflammatory Diseases Is Not Associated with Worse Obstetrical or Infant Outcomes and Seems to Reduce Risk of Maternal Severe Infection: The Results of the Emulated Target Trial BioGRIC
Background/Purpose: Many women with chronic rheumatic inflammatory diseases (CRID) stop tumor necrosis factor inhibitors (TNFi) treatment once pregnancy is confirmed to avoid potential adverse fetal…Abstract Number: 0594 • ACR Convergence 2023
Baseline Innate Immunity Transcriptional Signatures Act as Predictors of Response to Immunosuppressive and Biologic Treatments in Systemic Lupus Erythematosus While Disturbances Linked to p53-signaling Define “Resistant” Disease
Background/Purpose: Despite recent advances, the current state of SLE therapeutics remains largely empirical with existing immunosuppressive treatments failing to induce remission in over 40% of…
- « Previous Page
- 1
- …
- 13
- 14
- 15
- 16
- 17
- …
- 54
- Next Page »